Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study

What Was Tested

This clinical trial, phase ii paper looks at Octreotide.

The researchers assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN).

Ancillary studies evaluated hypertension, proteinuria, and vascular endothelial growth factor (VEGF) polymorphisms in predicting progression-free survival (PFS) and the predictive role of serum vitamin D in progression-free survival and proteinuria onset.

Who Took Part

The abstract describes 2 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

This prospective phase 2 study included 45 patients with WMD-NEN arising from various primary sites.

How the Study Was Run

Bevacizumab was continued until disease progression.

What Was Measured

The researchers assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN).

Ancillary studies evaluated hypertension, proteinuria, and vascular endothelial growth factor (VEGF) polymorphisms in predicting progression-free survival (PFS) and the predictive role of serum vitamin D in progression-free survival and proteinuria onset.

PubMed files the paper under topics including Administration, Metronomic, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Capecitabine, Deoxycytidine and Disease-Free Survival.

What This Means in Plain Language

This is a clinical trial, phase ii of Octreotide in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (BMC cancer), a journal based in England.

More context: the Octreotide compound page, all human trials.